The estimated Net Worth of Ann Hanham is at least $5.07 Tysiąc dollars as of 21 December 2020. Ann Hanham owns over 3,200 units of Scynexis Inc stock worth over $5,071 and over the last 10 years he sold SCYX stock worth over $0. In addition, he makes $0 as Director at Scynexis Inc.
Sign up
Ann Hanham SCYX stock SEC Form 4 insiders trading
Ann has made over 2 trades of the Scynexis Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 3,200 units of SCYX stock worth $20,000 on 21 December 2020.
The largest trade he's ever made was buying 4,225 units of Scynexis Inc stock on 25 May 2016 worth over $15,379. On average, Ann trades about 248 units every 56 days since 2014. As of 21 December 2020 he still owns at least 3,622 units of Scynexis Inc stock.
You can see the complete history of Ann Hanham stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ann Hanham biography
Dr. Ann F. Hanham, Ph.D. is directors of the Company since December 2008. Prior to becoming a Founding Partner and Managing Director of BAR Capital Management in December 2013, she was a General Partner with Burrill & Company, a life sciences venture capital firm from 2000 to 2013. From 1998 to 2000, Dr. Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune, Inc. From 1995 to 1998, she served as the Senior Director for Oncology Product Development at Otsuka Pharmaceuticals and from 1991 to 1995 as the Medical Director for Celtrix Pharmaceuticals. From 1988 to 1991, Dr. Hanham worked for Becton Dickinson in both regulatory and clinical affairs for the monoclonal antibody program, and from 1984 to 1988 as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada. She has served as a member of the board of directors of AliveCor since 2013, Endocyte, Inc. (NASDAQ: ECYT) since 2004, NewBridge since 2013 and Waterstone Pharmaceuticals, Inc. since 2008. She previously served as a member of the boards of directors of Acusphere Inc. (OTCMKTS: ACUS), Biomimetic Therapeutics Inc. (NASDAQ: BMTI ), Biotie Therapies Corp. (Nordic List: BTH1V), Immunicon Corp. (NASDAQ: IMMC ), Targacept Inc. (NASDAQ: TRGT), and TLC (Taiwan Liposome Company, Inc.) (GreTai Sec M: 1452:TT). Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986. Because of Dr. Hanham’s extensive clinical and regulatory experience, as well as her extensive experience in working with development stage biotechnology companies, we believe she is able to make valuable contributions to our board of directors.
How old is Ann Hanham?
Ann Hanham is 62, he's been the Director of Scynexis Inc since 2008. There are 4 older and 10 younger executives at Scynexis Inc. The oldest executive at Scynexis Inc is Patrick Langlois, 70, who is the Director.
What's Ann Hanham's mailing address?
Ann's mailing address filed with the SEC is 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY, NJ, 07302-6548.
Insiders trading at Scynexis Inc
Over the last 11 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado oraz Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.
What does Scynexis Inc do?
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
What does Scynexis Inc's logo look like?
Complete history of Ann Hanham stock trades at HTG Molecular Diagnostics Inc i Scynexis Inc
Scynexis Inc executives and stock owners
Scynexis Inc executives and other stock owners filed with the SEC include:
-
Dr. Marco Taglietti M.D.,
CEO, Pres & Director -
Dr. Marco Taglietti,
CEO, Pres & Director -
David Gonzalez Angulo,
Chief Medical Officer -
Eric Francois,
Chief Financial Officer -
Christine R. Coyne M.B.A.,
Chief Commercial Officer -
Philippe Tinmouth,
Director -
Jean-Yves Nothias,
Director -
Guy Macdonald,
Director -
Patrick Langlois,
Director -
David Hastings,
Director -
Ann Hanham,
Director -
Steven Gilman,
Director -
Laurent Arthaud,
Director -
Armando Anido,
Director -
David Angulo,
Chief Medical Officer -
Scott Sukenick,
General Counsel -
Nkechi Azie,
Vice President - Clinical Development -
Jim Maffezzoli,
Vice President of Sales and Marketing -
Eric Francois,
Chief Financial Officer -
Marco Taglietti,
President, Chief Executive Officer, Director -
Pamela Kirby,
Chairman of the Board -
Debbie Etchison,
Exec. Director of Communications -
Lawrence R. Hoffman CPA, Esq.,
Interim CFO & Principal Accounting Officer -
Dr. Rajeshwar Motheram,
Sr. VP of Pharmaceutical Devel. & Supply Chain -
Scott Sukenick J.D.,
Gen. Counsel & Corp. Sec. -
Patrick Machado,
Director -
Marion Mc Court,
Director -
Jr. Charles F Osborne,,
Chief Financial Officer -
Biopharma Partners Ii Lpalt...,
-
Carole Sable,
Chief Medical Officer -
Capital Ii Ventech,
10% owner -
Biotechnology Fund Fcpr,
10% owner -
Eileen Pruette,
General Counsel -
Genavent F.C.P.R.,
10% owner -
Mounia Chaoui,
Director -
Edward Penhoet,
Director -
Yves J Ribeill,
President and CEO -
Advisors Llcperceptive Life...,
-
Christine Coyne,
Chief Commercial Officer -
Ivor Macleod,
Chief Financial Officer